Lara J. Maxwell

Lara J. Maxwell

Auto-generated profile, based on publicly available information

Lara J. Maxwell

Faculty of Medicine, University of Ottawa, Ottawa, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2015 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LMLara J Maxwell
Lara J Maxwell
JZJane Zochling
Jane Zochling
ABAnnelies Boonen
Annelies Boonen
JSJasvinder Singh
Jasvinder Singh
MVMirella M S Veras
Mirella M S Veras
GWGeorge A Wells
George A Wells

15 September 2020 in BMJ
Verified
Journal Article
Closed access
PDF file
PTPeter Tugwell
Peter Tugwell
VWVivian Welch
Vivian Welch
SKSathya Karunananthan
Sathya Karunananthan
LMLara J Maxwell
Lara J Maxwell
EAElie Akl
Elie Akl
HWHoward White
Howard White
Replication is an essential part of the scientific method, yet replication of systematic reviews is too often overlooked, and done unnecessarily or poorly. Excessive replication (doing the same study repeatedly) is unethical and a cause of research wastage. This article provides consensus based guidance on when to replicate and not replicate systematic reviews.

15 February 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
MBMaarten Boers
Maarten Boers
DBDorcas E. Beaton
Dorcas E. Beaton
BSBeverley J. Shea
Beverley J. Shea
LMLara J. Maxwell
Lara J. Maxwell
SBSusan J. Bartlett
Susan J. Bartlett
PTPeter Tugwell
Peter Tugwell
Objective.: The Outcome Measures in Rheumatology (OMERACT) Filter 2.0 framework was developed in 2014 to aid core outcome set development by describing the full universe of “measurable aspects of health conditions” from which core domains can be selected. This paper provides elaborations and updated concepts (OMERACT Filter 2.1).Methods.: At OMERACT 2018, we discussed challenges in the framework application caused by unclear or ambiguous wording and terms and incompletely developed concepts.Results.: The updated OMERACT Filter 2.1 framework makes benefits and harms explicit, clarifies concepts, and improves naming of various terms.Conclusion.: We expect that the Filter 2.1 framework will improve the process of core set development.

15 January 2010 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
LMLara J. Maxwell
Lara J. Maxwell
JSJasvinder Singh
Jasvinder Singh
Objective. To perform a systematic review of efficacy and safety of abatacept in patients with rheumatoid arthritis (RA).

15 February 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
LMLara J. Maxwell
Lara J. Maxwell
DBDorcas E. Beaton
Dorcas E. Beaton
BSBeverley J. Shea
Beverley J. Shea
GWGeorge A. Wells
George A. Wells
MBMaarten Boers
Maarten Boers
PTPeter Tugwell
Peter Tugwell
Objective.: To describe the Outcome Measures in Rheumatology (OMERACT) Filter 2.1 methodology for core domain set selection.Methods.: The “OMERACT Way for Core Domain Set selection” framework consists of 3 stages: first, generating candidate domains through literature reviews and qualitative work, then a process of consensus to obtain agreement from those involved, and finally formal voting on the OMERACT Onion. The OMERACT Onion describes the placement of domains in layers/circles: mandatory in all trials/mandatory in specific circumstances (inner circle); important but optional (middle circle); or research agenda (outer circle). Five OMERACT working groups presented their core domain sets for endorsement by the OMERACT community. Tools including a workbook and whiteboard video were created to assist the process. The methods workshop at OMERACT 2018 introduced participants to this framework.Results.: The 5 OMERACT working groups achieved consensus on their proposed core domain sets. After the Methodology Workshop training exercise at OMERACT 2018, over 90% of participants voted that they were confident that they understood the process of core domain set selection.Conclusion.: The methods described in this paper were successfully used by the 5 working groups voting on domains at the OMERACT 2018 meeting, demonstrating the feasibility of the process. In addition, participants at OMERACT 2018 expressed increased confidence and understanding of the core domain set selection process after the training exercise. This methodology will continue to evolve, and we will use innovative technology such as whiteboard videos as a key part of our dissemination and implementation strategy for new methods.

1 February 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
DBDorcas E. Beaton
Dorcas E. Beaton
LMLara J. Maxwell
Lara J. Maxwell
BSBeverley J. Shea
Beverley J. Shea
GWGeorge A. Wells
George A. Wells
MBMaarten Boers
Maarten Boers
PTPeter Tugwell
Peter Tugwell
Objective.: Outcome Measures in Rheumatology (OMERACT) Filter 2.1 revised the process used for core outcome measurement set selection to add rigor and transparency in decision making. This paper describes OMERACT’s methodology for instrument selection.Methods.: We presented instrument selection processes, tools, and reporting templates at OMERACT 2018, introducing the concept of “3 pillars, 4 questions, 7 measurement properties, 1 answer.” Truth, discrimination, and feasibility are the 3 original OMERACT pillars. Based on these, we developed 4 signaling questions. We introduced the Summary of Measurement Properties table that summarizes the 7 measurement properties: truth (domain match, construct validity), discrimination [test-retest reliability, longitudinal construct validity (responsiveness), clinical trial discrimination, thresholds of meaning], and feasibility. These properties address a set of standards which, when met, answer the one question: Is there enough evidence to support the use of this instrument in clinical research of the benefits and harms of treatments in the population and study setting described? The OMERACT Filter 2.1 was piloted on 2 instruments by the Psoriatic Arthritis Working Group.Results.: The methodology was reviewed in a full plenary session and facilitated breakout groups. Tools to facilitate retention of the process (i.e., “The OMERACT Way”) were provided. The 2 instruments were presented, and the recommendation of the working group was endorsed in the first OMERACT Filter 2.1 Instrument Selection votes.Conclusion.: Instrument selection using OMERACT Filter 2.1 is feasible and is now being implemented.